How to control Natural Killer cells to improve stem cell transplant outcomes
- Research Opportunity
- PhD, Honours
- Project Status
- Medicine and Radiology
- Royal Melbourne Hospital
|David Ritchie||Personal web page|
The Royal Melbourne Hospital (RMH) is the largest provider of allogeneic haematopoietic stem cell transplantation (alloSCT) in Australia. AlloSCT is a complex but potentially curative procedure for patients with haematologic malignancies or bone marrow failure syndromes. The fundamental principle of alloSCT is that a donor’s haematopoietic stem cells (or graft), when infused into the recipient, will develop into a new set of immunologically active cells that recognise tumour cells as foreign and contain or destroy them. We must find means to lower conditioning toxicity, promote donor engraftment and limit graft-versus host disease in order to improve alloSCT outcomes. The ACRF Translational Research Laboratory (located at the Victorian Comprehensive Cancer Centre) has AEEC-approved projects to investigate the role of natural killer (NK) cells in regulating donor cell engraftment after alloSCT.
Our innovative approach, which promotes engraftment whilst lessening the risks of alloSCT, utilises drug therapies that are already available clinically. This project will utilise novel mouse models of alloSCT to investigate pharmacological inhibition of NK cells in combination with reduced conditioning, to improve long-term engraftment and anti-cancer responses. Techniques used in this project include immunoprofiling of mouse alloSCT and acute myeloid leukaemia models using multi-parameter flow cytometry, cytokine bead array, histology, and bioluminescence imaging. This project is based in the ACRF Translational Research Laboratory, with co-supervision and collaboration from the Walter and Eliza Hall Institute.
This research project is available to PhD, Honours students to join as part of their thesis.
Please contact the supervisor to discuss your options.